Prognostic factors and seizure outcome in posterior reversible
encephalopathy syndrome (PRES) in children with hematological
malignancies and bone marrow failure: A retrospective
monocentric study

J 2019

Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study

DANHOFER, Pavlína, Michaela HABALOVÁ, Dáša ČERNÁ, Danica ZAPLETALOVÁ, Ondřej HORÁK et. al.

Základní údaje

Originální název

Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study

Autoři

DANHOFER, Pavlína (203 Česká republika, garant, domácí), Michaela HABALOVÁ (203 Česká republika, domácí), Dáša ČERNÁ (703 Slovensko, domácí), Danica ZAPLETALOVÁ (703 Slovensko, domácí), Ondřej HORÁK (203 Česká republika, domácí), Štefánia AULICKÁ (703 Slovensko, domácí), Lenka JUŘÍKOVÁ (203 Česká republika, domácí), Jiří DOMANSKÝ (203 Česká republika, domácí), Petra KOVALČÍKOVÁ (203 Česká republika, domácí), Tomáš PAVLÍK (203 Česká republika, domácí), Jaroslav ŠTĚRBA (203 Česká republika, domácí) a Hana OŠLEJŠKOVÁ (203 Česká republika, domácí)

Vydání

Seizure-European journal of epilepsy, London, W.B. Saunders Ltd. 2019, 1059-1311

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.522

Kód RIV

RIV/00216224:14110/19:00112351

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.seizure.2019.08.007

UT WoS

000503322700001

Klíčová slova anglicky

PRES; Children; Oncology; Seizure; MRI; Prognosis

Štítky

14110320, 14110321, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 3. 2020 12:13, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: The aim of this study was to evaluate seizure outcome in children with hematological malignancies and PRES and to identify prognostic factors that could help manage the syndrome. Method: We retrospectively reviewed the report data of 21 patients diagnosed with hematological malignancy or aplastic anemia and PRES between 2008 and 2018. Basic demographic data, oncology treatment, presympto-matic hypertension before PRES manifestation, neurological status, seizure type, and EEG and MRI findings at PRES onset and at the one-year follow-up visit were studied. Patients who developed remote symptomatic seizures or epilepsy were identified. Results: We included 21 children (11 females and 10 males) in the study. Sixteen patients (76.2%) were diagnosed with ALL and the rest individually with AML, CML, T-lymphoma, Burkitt lymphoma, and severe aplastic anemia. Presymptomatic hypertension (PSH) was evaluated in 19 patients and was present in 18 (94.7%). The duration was 9 h and more in 16 patients (88.8%); the severity was grade II in 12 patients (66.7%). Seizures as the initial symptom of PRES were present in 17 patients (80.9%). Four patients (19.0%) were assessed with remote symptomatic seizures. Two of them (9.5%) had ongoing seizures at the one-year follow-up visit and were diagnosed with epilepsy. The presence of gliosis on follow-up MRI indicated worse outcome with development of epilepsy (without statistical significance). Conclusions: PRES syndrome has an overall good prognosis and the evolution to epilepsy is rare. The severity and duration of PSH or seizure severity and EEG findings at PRES onsetwere not associated with worse neurological outcomes in this study.

Návaznosti

MUNI/A/1586/2018, interní kód MU

Název: Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medecine" a "N-of-1 clinical trials" (Akronym: Personalizovaná léčba v dětské onkologii)

Investor: Masarykova univerzita, Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medecine" a "N-of-1 clinical trials", DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

ROZV/24/LF/2018, interní kód MU

Název: LF - Příspěvek na IP 2108

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, LF - Příspěvek na IP 2108, Interní rozvojové projekty

Citovat

DANHOFER, Pavlína, Michaela HABALOVÁ, Dáša ČERNÁ, Danica ZAPLETALOVÁ, Ondřej HORÁK, Štefánia AULICKÁ, Lenka JUŘÍKOVÁ, Jiří DOMANSKÝ, Petra KOVALČÍKOVÁ, Tomáš PAVLÍK, Jaroslav ŠTĚRBA a Hana OŠLEJŠKOVÁ. Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study. Seizure-European journal of epilepsy. London: W.B. Saunders Ltd., 2019, roč. 72, NOV 2019, s. 1-10. ISSN 1059-1311. Dostupné z: https://dx.doi.org/10.1016/j.seizure.2019.08.007.

@article{1603660,
   author = {Danhofer, Pavlína and Habalová, Michaela and Černá, Dáša and Zapletalová, Danica and Horák, Ondřej and Aulická, Štefánia and Juříková, Lenka and Domanský, Jiří and Kovalčíková, Petra and Pavlík, Tomáš and Štěrba, Jaroslav and Ošlejšková, Hana},
   article_location = {London},
   article_number = {NOV 2019},
   doi = {http://dx.doi.org/10.1016/j.seizure.2019.08.007},
   keywords = {PRES; Children; Oncology; Seizure; MRI; Prognosis},
   language = {eng},
   issn = {1059-1311},
   journal = {Seizure-European journal of epilepsy},
   title = {Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study},
   url = {http://dx.doi.org/10.1016/j.seizure.2019.08.007},
   volume = {72},
   year = {2019}
}

TY  - JOUR
ID  - 1603660
AU  - Danhofer, Pavlína - Habalová, Michaela - Černá, Dáša - Zapletalová, Danica - Horák, Ondřej - Aulická, Štefánia - Juříková, Lenka - Domanský, Jiří - Kovalčíková, Petra - Pavlík, Tomáš - Štěrba, Jaroslav - Ošlejšková, Hana
PY  - 2019
TI  - Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study
JF  - Seizure-European journal of epilepsy
VL  - 72
IS  - NOV 2019
SP  - 1-10
EP  - 1-10
PB  - W.B. Saunders Ltd.
SN  - 10591311
KW  - PRES
KW  - Children
KW  - Oncology
KW  - Seizure
KW  - MRI
KW  - Prognosis
UR  - http://dx.doi.org/10.1016/j.seizure.2019.08.007
L2  - http://dx.doi.org/10.1016/j.seizure.2019.08.007
N2  - Purpose: The aim of this study was to evaluate seizure outcome in children with hematological malignancies and PRES and to identify prognostic factors that could help manage the syndrome. Method: We retrospectively reviewed the report data of 21 patients diagnosed with hematological malignancy or aplastic anemia and PRES between 2008 and 2018. Basic demographic data, oncology treatment, presympto-matic hypertension before PRES manifestation, neurological status, seizure type, and EEG and MRI findings at PRES onset and at the one-year follow-up visit were studied. Patients who developed remote symptomatic seizures or epilepsy were identified. Results: We included 21 children (11 females and 10 males) in the study. Sixteen patients (76.2%) were diagnosed with ALL and the rest individually with AML, CML, T-lymphoma, Burkitt lymphoma, and severe aplastic anemia. Presymptomatic hypertension (PSH) was evaluated in 19 patients and was present in 18 (94.7%). The duration was 9 h and more in 16 patients (88.8%); the severity was grade II in 12 patients (66.7%). Seizures as the initial symptom of PRES were present in 17 patients (80.9%). Four patients (19.0%) were assessed with remote symptomatic seizures. Two of them (9.5%) had ongoing seizures at the one-year follow-up visit and were diagnosed with epilepsy. The presence of gliosis on follow-up MRI indicated worse outcome with development of epilepsy (without statistical significance). Conclusions: PRES syndrome has an overall good prognosis and the evolution to epilepsy is rare. The severity and duration of PSH or seizure severity and EEG findings at PRES onsetwere not associated with worse neurological outcomes in this study.
ER  -

DANHOFER, Pavlína, Michaela HABALOVÁ, Dáša ČERNÁ, Danica ZAPLETALOVÁ, Ondřej HORÁK, Štefánia AULICKÁ, Lenka JUŘÍKOVÁ, Jiří DOMANSKÝ, Petra KOVALČÍKOVÁ, Tomáš PAVLÍK, Jaroslav ŠTĚRBA a Hana OŠLEJŠKOVÁ. Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study. \textit{Seizure-European journal of epilepsy}. London: W.B. Saunders Ltd., 2019, roč.~72, NOV 2019, s.~1-10. ISSN~1059-1311. Dostupné z: https://dx.doi.org/10.1016/j.seizure.2019.08.007.

Podrobný výpis o publikaci